Dupixent — Medica

Initial criteria

• age ≥ 18 years
• ≥ 20 identifiable nodular lesions on arms/legs/trunk
• pruritus for ≥ 6 weeks
• either: prurigo nodularis not medication-induced/secondary OR secondary cause identified and managed
• tried at least one high- or super-high-potency prescription topical corticosteroid applied daily for ≥ 14 consecutive days with inadequate efficacy
• prescribed by or in consultation with allergist, immunologist, or dermatologist

Reauthorization criteria

• already received ≥ 6 months of Dupixent therapy
• beneficial clinical response (reduced nodular lesion count OR decreased pruritus OR reduced nodular lesion size)

Approval duration

initial 6 months, renewal 1 year